[Clinical efficacy and safety of recombinant human-growth hormone in the treatment of idiopathic asthenospermia].
OBJECTIVE
To evaluate the clinical efficacy and safety of recombinant human-growth hormone (rhGH) in the treatment of idiopathic asthenospermia.


METHODS
Forty patients with idiopathic asthenospermia were recruited, randomly divided into an rhGH group and a control group and treated for 3 months. In addition to routine treatment, the rhGH group (n = 18) received rhGH, while the control group (n = 18) underwent the routine treatment only. Before and after the treatment, semen samples were obtained, analyzed and graded according to the WHO laboratory manual, and the serum sexual hormone, thyroxin, liver and kidney function, blood cholesterol and blood glucose level were detected.


RESULTS
Sperm vitality was statistically increased, (28.60 +/- 32.89) % in the rhGH group and (8.42 +/- 25.87) % in the control (P < 0.01), and so was sperm (a + b) motility, (18.56 +/- 21.19) % in the rhGH group and (8.12 +/- 24.34) % in the control (P < 0.05).


CONCLUSIONS
rhGH can be used safely as an effective supplement to medicinal treatment of idiopathic asthenospermia.
Chen
Ting
T
International Peace Maternity and Child Health Hospital, Shanghai Jiaotong University, China Center for Reproductive Health Technical Instruction, Shanghai 200030, China. 28259145@163.com
Cheng
Huai-jin
HJ
D053627:Asthenozoospermia / Q000178:diet therapy; D019382:Human Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy*; D008297:Male; D013076:Sperm Count; D013081:Sperm Motility; D016896:Treatment Outcome
D019382:Human Growth Hormone